menu
    • menu
    [{"orgOrder":0,"company":"Medsenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Neurology","graph2":"Preclinical","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medsenic \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Medsenic \/ Inapplicable"},{"orgOrder":0,"company":"Brainever","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Human Homeoprotein Engrailed 1","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Brainever","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brainever \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Brainever \/ Inapplicable"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"CTx-TFEB","moa":"Transcription Factor EB","graph1":"Neurology","graph2":"Preclinical","graph3":"Coave Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coave Therapeutics \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Coave Therapeutics \/ ALS Association"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2025","type":"Series A Financing","leadProduct":"CTx-TFEB","moa":"Transcription Factor EB","graph1":"Neurology","graph2":"Preclinical","graph3":"Coave Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Coave Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"4","companyTruncated":"Coave Therapeutics \/ Novo Holdings"},{"orgOrder":0,"company":"Corlieve Therapeutics","sponsor":"Uniqure","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"AMT-260","moa":"Kainate receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Corlieve Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corlieve Therapeutics \/ Uniqure","highestDevelopmentStatusID":"4","companyTruncated":"Corlieve Therapeutics \/ Uniqure"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Institute of Neurodegenerative Diseases of Bordeaux","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"CTx-TFEB","moa":"Transcription Factor EB","graph1":"Neurology","graph2":"Preclinical","graph3":"Coave Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coave Therapeutics \/ Institute of Neurodegenerative Diseases of Bordeaux","highestDevelopmentStatusID":"4","companyTruncated":"Coave Therapeutics \/ Institute of Neurodegenerative Diseases of Bordeaux"},{"orgOrder":0,"company":"Affilogic","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"APL-1030","moa":"C3 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Affilogic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affilogic \/ Apellis Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Affilogic \/ Apellis Pharmaceuticals"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"ABL Bio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"CTx-GBA1","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Coave Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coave Therapeutics \/ ABL Bio","highestDevelopmentStatusID":"4","companyTruncated":"Coave Therapeutics \/ ABL Bio"},{"orgOrder":0,"company":"Alzprotect","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ezeprogind","moa":"PGRN","graph1":"Neurology","graph2":"Preclinical","graph3":"Alzprotect","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alzprotect \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alzprotect \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Coave Therapeutics

                            France arrow
                            Pharmex
                            Not Confirmed

                            Coave Therapeutics

                            France arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTx-TFEB

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Novo Holdings

                            Deal Size : $33.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Coave Secures €32M Series A to Advance Genetic Medicine Pipeline

                            Details : The funding will also enable Coave to advance its lead preclinical assets toward clinical development of CTx-TFEB. It is being evaluated for treating Amyotrophic Lateral Sclerosis.

                            Product Name : CTx-TFEB

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 09, 2025

                            Lead Product(s) : CTx-TFEB

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Novo Holdings

                            Deal Size : $33.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Coave Therapeutics

                            France arrow
                            Pharmex
                            Not Confirmed

                            Coave Therapeutics

                            France arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTx-TFEB

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : ALS Association

                            Deal Size : $2.9 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Coave Therapeutics Receives Grant from Als Association for CTx-Tfeb Program

                            Details : The funding will support Coave in developing CTx-TFEB, which is being evaluated in preclinical studies for multiple system atrophy treatment.

                            Product Name : CTx-TFEB

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 29, 2024

                            Lead Product(s) : CTx-TFEB

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : ALS Association

                            Deal Size : $2.9 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Coave Therapeutics

                            France arrow
                            Pharmex
                            Not Confirmed

                            Coave Therapeutics

                            France arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTx-TFEB

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Institute of Neurodegenerative Diseases of Bordeaux

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bordeaux to D...

                            Details : The collaboration will explore the development of gene therapy product CTx-TFEB, targeting the transcription factor EB (TFEB) for the treatment of alpha-synucleinopathies, such as Multiple System Atrophy (MSA) and idiopathic Parkinson’s disease (PD).

                            Product Name : CTx-TFEB

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 14, 2022

                            Lead Product(s) : CTx-TFEB

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Institute of Neurodegenerative Diseases of Bordeaux

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Coave Therapeutics

                            France arrow
                            Pharmex
                            Not Confirmed

                            Coave Therapeutics

                            France arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTx-GBA1

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : ABL Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Coave Therapeutics and ABL Enter Into Strategic Collaboration to Develop Gene Therapy Manufacturing Processes ...

                            Details : Under the two-stage collaboration both companies will initially combine their complementary expertise to co-develop manufacturing technologies for AAV-based gene therapy products including CTx-GBA1.

                            Product Name : CTx-GBA1

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 06, 2022

                            Lead Product(s) : CTx-GBA1

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : ABL Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Affilogic

                            France arrow
                            Pharmex
                            Not Confirmed

                            Affilogic

                            France arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APL-1030

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Apellis Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Apellis Expands R&D Collaboration with Affilogic to Develop Targeted Complement Therapies for Delivery into th...

                            Details : APL-1030, a potential first-in-class, brain-active C3 inhibitor for neurodegenerative and other complement-driven diseases, and APL-2006, an ophthalmological candidate in development to treat both wet age-related macular degeneration (AMD) and geographic...

                            Product Name : APL-1030

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 22, 2022

                            Lead Product(s) : APL-1030

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Apellis Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Medsenic

                            France arrow
                            Pharmex
                            Not Confirmed

                            Medsenic

                            France arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Medsenic Receives Notice of Approval for a New US Patent Broadening the Use of Arsenic Trioxide to Treat the R...

                            Details : Arsenic trioxide has the unique property of increasing cellular oxidative stress to the point where it induces cell death of activated cells (enhanced apoptosis). It also has an effect on pro-inflammatory cytokines.

                            Product Name : Arscimed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            September 29, 2021

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Corlieve Therapeutics

                            France arrow
                            Pharmex
                            Not Confirmed

                            Corlieve Therapeutics

                            France arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMT-260

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Uniqure

                            Deal Size : $298.1 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy ...

                            Details : Under the license and collaboration agreement, REGENXBIO received equity in Corlieve and is eligible to receive milestone payments and royalties on net sales of AMT-260.

                            Product Name : AMT-260

                            Product Type : Cell and Gene therapy

                            Upfront Cash : $54.6 million

                            June 22, 2021

                            Lead Product(s) : AMT-260

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Uniqure

                            Deal Size : $298.1 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Brainever

                            France arrow
                            Pharmex
                            Not Confirmed

                            Brainever

                            France arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human Homeoprotein Engrailed 1

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BrainEver Receives FDA Orphan Drug Designation for BREN-02, for the Treatment of Amyotrophic Lateral Sclerosis

                            Details : U.S. FDA has granted orphan drug designation to BrainEver's product BREN-02, the recombinant human homeoprotein Engrailed 1, for the treatment of amyotrophic lateral sclerosis.

                            Product Name : BREN-02

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            November 23, 2020

                            Lead Product(s) : Recombinant Human Homeoprotein Engrailed 1

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Alzprotect

                            France arrow
                            Pharmex
                            Not Confirmed

                            Alzprotect

                            France arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ezeprogind

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alzprotect Strengthens Its Intellectual Property Portfolio for Its First-in-Class Clinical Stage Drug Ezeprogi...

                            Details : The patent complements the portfolio of patents covering Ezéprogind and its therapeutic uses already granted in Europe, and in 11 other countries including Japan and China.

                            Product Name : AZP2006

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 23, 2020

                            Lead Product(s) : Ezeprogind

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth